Purdue Withdraws Palladone At FDA's Request Due To Alcohol Interaction

The company is immediately pulling extended-release hydromorphone off the market because of the potential for rapid release of the active ingredient into the bloodstream when the product is taken with alcohol, FDA and Purdue announce. FDA and Purdue note they have not received reports of alcohol-related serious adverse events with the opioid.